(0.94%) 5 111.66 points
(0.96%) 38 593 points
(1.70%) 16 110 points
(-0.71%) $78.39
(3.39%) $2.10
(-0.34%) $2 301.80
(-0.78%) $26.62
(0.03%) $962.90
(-0.43%) $0.928
(-1.35%) $10.84
(-0.15%) $0.797
(0.31%) $91.41
3 days till quarter result
(amc 2024-05-06)
Expected move: +/- 6.55%
1.34% $ 11.76
@ $11.63
Wydano: 2 geg. 2024 @ 20:41
Zwrot: 1.12%
Poprzedni sygnał: geg. 2 - 19:36
Poprzedni sygnał:
Zwrot: 0.26 %
Live Chart Being Loaded With Signals
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets...
Stats | |
---|---|
Dzisiejszy wolumen | 1.15M |
Średni wolumen | 9.00M |
Kapitalizacja rynkowa | 14.00B |
EPS | $0 ( 2024-02-28 ) |
Następna data zysków | ( $0 ) 2024-05-06 |
Last Dividend | $0.120 ( 2023-11-22 ) |
Next Dividend | $0 ( N/A ) |
P/E | 235.10 |
ATR14 | $0.235 (2.00%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-18 | Le Goff Corinne | Buy | 110 162 | Restricted Stock Units |
2024-04-18 | Le Goff Corinne | Buy | 78 688 | Restricted Stock Units |
2024-04-15 | Le Goff Corinne | Buy | 0 | |
2024-04-02 | Malik Rajiv | Buy | 18 845 | Restricted Stock Units |
2024-03-13 | Mauro Anthony | Sell | 250 000 | Common Stock |
INSIDER POWER |
---|
9.40 |
Last 99 transactions |
Buy: 1 339 847 | Sell: 1 117 278 |
Wolumen Korelacja
Viatris Inc. Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
MMAC | 0.897 |
NETE | 0.888 |
SRAC | 0.833 |
AMRB | 0.83 |
RAVN | 0.829 |
BRKH | 0.824 |
DOOO | 0.824 |
EUSG | 0.819 |
BOCH | 0.817 |
TKNO | 0.816 |
10 Najbardziej negatywne korelacje | |
---|---|
SVOK | -0.94 |
PAIC | -0.907 |
SVAC | -0.9 |
RMRM | -0.883 |
FEYE | -0.846 |
TLGT | -0.841 |
SPRT | -0.83 |
FTOCU | -0.823 |
FTOC | -0.815 |
OPCH | -0.808 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Viatris Inc. Korelacja - Waluta/Towar
Viatris Inc. Finanse
Annual | 2023 |
Przychody: | $15.38B |
Zysk brutto: | $6.57B (42.70 %) |
EPS: | $0.0456 |
FY | 2023 |
Przychody: | $15.38B |
Zysk brutto: | $6.57B (42.70 %) |
EPS: | $0.0456 |
FY | 2022 |
Przychody: | $16.26B |
Zysk brutto: | $6.50B (39.95 %) |
EPS: | $1.710 |
FY | 2021 |
Przychody: | $17.89B |
Zysk brutto: | $5.58B (31.17 %) |
EPS: | $-2.11 |
Financial Reports:
No articles found.
Viatris Inc. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0.120 (N/A) |
$0.120 (N/A) |
$0.120 (N/A) |
$0.120 (N/A) |
$0.240 (N/A) |
$0.120 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.00741 | 1986-12-24 |
Last Dividend | $0.120 | 2023-11-22 |
Next Dividend | $0 | N/A |
Payout Date | 2023-12-15 | |
Next Payout Date | N/A | |
# dividends | 88 | -- |
Total Paid Out | $2.99 | -- |
Avg. Dividend % Per Year | 2.32% | -- |
Score | 5.02 | -- |
Div. Sustainability Score | 6.81 | |
Div.Growth Potential Score | 4.62 | |
Div. Directional Score | 5.72 | -- |
Year | Amount | Yield |
---|---|---|
1986 | $0.00741 | 0.28% |
1987 | $0.0148 | 0.88% |
1988 | $0.0111 | 0.86% |
1989 | $0.0148 | 1.13% |
1990 | $0.0222 | 0.63% |
1991 | $0.0296 | 1.01% |
1992 | $0.0326 | 0.53% |
1993 | $0.0416 | 0.46% |
1994 | $0.0564 | 0.78% |
1995 | $0.0652 | 0.85% |
1996 | $0.0712 | 0.70% |
1997 | $0.0712 | 0.97% |
1998 | $0.0712 | 0.80% |
1999 | $0.0712 | 0.53% |
2000 | $0.0712 | 0.66% |
2001 | $0.0712 | 0.65% |
2002 | $0.0756 | 0.47% |
2003 | $0.0966 | 0.61% |
2004 | $0.120 | 0.48% |
2005 | $0.210 | 1.20% |
2006 | $0.240 | 1.20% |
2007 | $0.120 | 0.60% |
2008 | $0 | 0.00% |
2009 | $0 | 0.00% |
2010 | $0 | 0.00% |
2011 | $0 | 0.00% |
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0.330 | 1.78% |
2022 | $0.480 | 3.38% |
2023 | $0.600 | 5.27% |
2024 | $0 | 0.00% |
With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.00355 | 1.500 | 9.93 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.00115 | 1.200 | 9.96 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.00263 | 1.500 | -1.082 | -1.623 | [0.1 - 1] |
payoutRatioTTM | 10.52 | -1.000 | 10.00 | -10.00 | [0 - 1] |
currentRatioTTM | 1.572 | 0.800 | 7.14 | 5.71 | [1 - 3] |
quickRatioTTM | 0.658 | 0.800 | -0.833 | -0.666 | [0.8 - 2.5] |
cashRatioTTM | 0.128 | 1.500 | -0.401 | -0.602 | [0.2 - 2] |
debtRatioTTM | 0.382 | -1.500 | 3.63 | -5.45 | [0 - 0.6] |
interestCoverageTTM | 1.886 | 1.000 | -0.413 | -0.413 | [3 - 30] |
operatingCashFlowPerShareTTM | 2.33 | 2.00 | 9.22 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 1.937 | 2.00 | 9.03 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.890 | -1.500 | 6.44 | -9.66 | [0 - 2.5] |
grossProfitMarginTTM | 0.419 | 1.000 | 6.36 | 6.36 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0708 | 1.000 | -0.585 | -0.585 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.154 | 1.000 | -0.257 | -0.257 | [0.2 - 2] |
assetTurnoverTTM | 0.323 | 0.800 | -1.178 | -0.943 | [0.5 - 2] |
Total Score | 6.81 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 254.50 | 1.000 | 10.00 | 0 | [1 - 100] |
returnOnEquityTTM | 0.00263 | 2.50 | -0.695 | -1.623 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 1.937 | 2.00 | 9.35 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 4.14 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 2.33 | 2.00 | 9.22 | 10.00 | [0 - 30] |
payoutRatioTTM | 10.52 | 1.500 | 10.00 | -10.00 | [0 - 1] |
pegRatioTTM | -1.597 | 1.500 | -10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.182 | 1.000 | 7.96 | 0 | [0.1 - 0.5] |
Total Score | 4.62 |
Viatris Inc.
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej